MY149152A - Percutaneous absorption preparations of antimentia drugs - Google Patents
Percutaneous absorption preparations of antimentia drugsInfo
- Publication number
- MY149152A MY149152A MYPI20084469A MYPI20084469A MY149152A MY 149152 A MY149152 A MY 149152A MY PI20084469 A MYPI20084469 A MY PI20084469A MY PI20084469 A MYPI20084469 A MY PI20084469A MY 149152 A MY149152 A MY 149152A
- Authority
- MY
- Malaysia
- Prior art keywords
- ester
- meth
- donepezil
- alkyl
- acrylate
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 8
- -1 SEBACATE ESTER Chemical class 0.000 abstract 4
- 229960003530 donepezil Drugs 0.000 abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 230000001464 adherent effect Effects 0.000 abstract 2
- 150000001733 carboxylic acid esters Chemical class 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 229940116351 sebacate Drugs 0.000 abstract 2
- 150000005846 sugar alcohols Polymers 0.000 abstract 2
- 229920001567 vinyl ester resin Polymers 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000012982 microporous membrane Substances 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79829606P | 2006-05-08 | 2006-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY149152A true MY149152A (en) | 2013-07-15 |
Family
ID=38667540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20084469A MY149152A (en) | 2006-05-08 | 2006-12-25 | Percutaneous absorption preparations of antimentia drugs |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7858114B2 (enExample) |
| EP (1) | EP2016939B1 (enExample) |
| JP (1) | JP5122445B2 (enExample) |
| KR (1) | KR20090009951A (enExample) |
| CN (1) | CN101460156B (enExample) |
| AU (1) | AU2006343077B2 (enExample) |
| BR (1) | BRPI0621655A2 (enExample) |
| CA (1) | CA2651596C (enExample) |
| ES (1) | ES2466647T3 (enExample) |
| IL (1) | IL195174A0 (enExample) |
| IN (1) | IN266817B (enExample) |
| MY (1) | MY149152A (enExample) |
| NO (1) | NO20084614L (enExample) |
| NZ (1) | NZ572809A (enExample) |
| RU (1) | RU2428179C2 (enExample) |
| WO (1) | WO2007129427A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573115B (zh) * | 2006-12-01 | 2012-06-06 | 日东电工株式会社 | 抑制含有多奈哌齐的贴剂着色的方法、及降低多奈哌齐类似物的生成量的方法 |
| KR101408488B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법 |
| CA2719605C (en) * | 2008-03-25 | 2016-07-12 | Teikoku Seiyaku Co., Ltd. | Transdermally absorbable preparation |
| US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| EP2279739B2 (en) * | 2008-05-30 | 2018-02-28 | Nitto Denko Corporation | Donepezil-containing patch preparation and packaging thereof |
| BRPI0912099A2 (pt) * | 2008-05-30 | 2015-10-06 | Eisai R&D Man Co Ltd | preparação percutaneamente absorvível |
| US20100080842A1 (en) * | 2008-09-30 | 2010-04-01 | Jianye Wen | Transdermal extended-delivery donepezil compositions and methods for using the same |
| US8858983B2 (en) | 2009-04-30 | 2014-10-14 | Medtronic, Inc. | Antioxidants and antimicrobial accessories including antioxidants |
| KR101325104B1 (ko) * | 2009-09-16 | 2013-11-07 | 주식회사 삼양바이오팜 | 경피 투여 제형 및 그 제조 방법 |
| KR20120101704A (ko) * | 2009-12-16 | 2012-09-14 | 고토 다케시 | 항인지증 약물의 경피흡수제제 |
| JP2012236773A (ja) * | 2009-12-16 | 2012-12-06 | Goto Takeshi | 抗認知症薬物の経皮吸収製剤 |
| TW201143817A (en) * | 2009-12-16 | 2011-12-16 | Goto Takeshi | Transdermally absorbed preparation of anti-dementia drug |
| US10076502B2 (en) | 2009-12-22 | 2018-09-18 | Luye Pharma Ag | Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
| US8962014B2 (en) * | 2009-12-22 | 2015-02-24 | Acino Ag | Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| NZ605352A (en) * | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
| RS54173B1 (sr) | 2010-12-14 | 2015-12-31 | Acino Ag | Transdermalni terapijski sistem za davanje aktivne supstance |
| US8911427B2 (en) * | 2010-12-28 | 2014-12-16 | Medtronic, Inc. | Therapeutic agent reservoir delivery system |
| TWI433904B (zh) * | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
| KR101054317B1 (ko) | 2011-01-28 | 2011-08-08 | 신신제약 주식회사 | 리바스티그민을 함유하는 경피흡수제제 |
| KR101317158B1 (ko) | 2011-02-18 | 2013-10-15 | 조선대학교산학협력단 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
| BR112013029945A2 (pt) * | 2011-05-20 | 2017-01-31 | Sk Chemicals Co Ltd | emplastro contendo rivastigmina |
| KR101395557B1 (ko) * | 2011-08-25 | 2014-05-16 | 아이큐어 주식회사 | 경피 흡수 제제 및 그 제조방법 |
| KR101239150B1 (ko) | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| KR101964295B1 (ko) * | 2012-09-05 | 2019-04-01 | 주식회사 한독 | 피부 자극이 감소된 메만틴 경피전달 시스템 |
| KR102171152B1 (ko) * | 2012-12-13 | 2020-10-29 | 하. 룬드벡 아크티에셀스카브 | 보르티옥세틴 및 도네페질을 포함하는 조성물 |
| JP6151935B2 (ja) * | 2013-03-11 | 2017-06-21 | 日東電工株式会社 | 経皮吸収促進用組成物および貼付製剤 |
| CN106456562B (zh) | 2014-02-20 | 2020-01-31 | 安能泰制药有限公司 | 含有多奈哌齐的透皮药物递送系统 |
| EP3310348B1 (en) | 2015-06-22 | 2020-08-05 | Corium, Inc. | Transdermal adhesive composition comprising a poorly soluble therapeutic agent |
| JP6148416B2 (ja) | 2015-06-29 | 2017-06-14 | 積水化学工業株式会社 | コアシェル構造体及び外用剤 |
| US10966936B2 (en) | 2015-12-30 | 2021-04-06 | Corium, Inc. | Systems comprising a composite backing and methods for long term transdermal administration |
| CA3028436A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| MX2019001104A (es) * | 2016-07-27 | 2019-10-02 | Corium Int Inc | Sistemas de suministro transdermico de memantina. |
| WO2018022814A1 (en) * | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| US9993466B2 (en) * | 2016-07-27 | 2018-06-12 | Corium International, Inc. | Donepezil transdermal delivery system |
| RU2748651C2 (ru) * | 2017-02-28 | 2021-05-28 | Кимберли-Кларк Ворлдвайд, Инк. | Синергическая композиция для сохранения здорового баланса микрофлоры |
| CN108096690B (zh) * | 2017-04-07 | 2019-08-20 | 杭州多泰科技有限公司 | 一种诱导循环肿瘤细胞转移的可移植支架的制备方法 |
| KR102033686B1 (ko) | 2017-05-19 | 2019-10-18 | 보령제약 주식회사 | 도네페질을 함유하는 마이크로니들 경피 패치 |
| CN111132669A (zh) * | 2017-07-26 | 2020-05-08 | 考里安公司 | 具有带溶剂填充孔的微孔膜的透皮递送系统 |
| CA3085342A1 (en) | 2017-12-13 | 2019-06-20 | Corium, Inc. | Method for depot creation during transdermal drug delivery |
| US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| CN108926549A (zh) * | 2018-09-27 | 2018-12-04 | 安徽安科余良卿药业有限公司 | 卡巴拉汀凝胶贴膏及其制备方法 |
| US20220175812A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| KR102489860B1 (ko) * | 2021-09-02 | 2023-01-19 | 동아에스티 주식회사 | 메만틴 에난트산염을 포함하는 치매 치료용 경피흡수 제제 |
| CN115957200A (zh) * | 2023-02-23 | 2023-04-14 | 广州新济药业科技有限公司 | 一种美金刚透皮贴剂及制备方法 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI921121A0 (fi) | 1989-09-14 | 1992-03-16 | Cygnus Research Corp | Transdermal doseringsanordning med foerdroejd start. |
| JP2977254B2 (ja) | 1990-09-04 | 1999-11-15 | 積水化学工業株式会社 | 経皮吸収貼付剤 |
| US5273756A (en) | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
| JPH06199659A (ja) * | 1992-10-28 | 1994-07-19 | Hisamitsu Pharmaceut Co Inc | 経皮治療用装置 |
| ATE149349T1 (de) * | 1993-06-25 | 1997-03-15 | Alza Corp | Einarbeitung eines poly-n-vinylamids in ein transdermales system |
| FR2717689B1 (fr) * | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base de copolymère styrène-isoprène-styrène. |
| US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| DE19533772C1 (de) * | 1995-09-12 | 1998-01-02 | Hexal Ag | Tacrin/Selegilin-Pflaster |
| DE19653605C2 (de) * | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems |
| JPH10315016A (ja) | 1997-05-15 | 1998-12-02 | Nissan Diesel Motor Co Ltd | チャック装置 |
| JP3987655B2 (ja) * | 1998-03-03 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
| DE19918106A1 (de) * | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern |
| GB9917290D0 (en) * | 1999-07-22 | 1999-09-22 | Glaxo Wellcome Spa | Pharmaceutical composition |
| DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| FR2814368B1 (fr) * | 2000-09-26 | 2004-05-07 | Pf Medicament | Preparation pharmaceutique a base d'oxans |
| JP4057418B2 (ja) * | 2000-11-07 | 2008-03-05 | 久光製薬株式会社 | 経皮吸収型製剤 |
| DE10060550C1 (de) | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
| JP4394443B2 (ja) * | 2001-10-17 | 2010-01-06 | 久光製薬株式会社 | 経皮吸収型製剤 |
| DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| JP4274951B2 (ja) * | 2004-01-07 | 2009-06-10 | 久光製薬株式会社 | 異型断面繊維を使用した支持体を有するテーピング型貼付剤 |
| JPWO2005115355A1 (ja) * | 2004-05-28 | 2008-03-27 | 久光製薬株式会社 | 貼付製剤 |
-
2006
- 2006-12-25 ES ES06835183.2T patent/ES2466647T3/es active Active
- 2006-12-25 JP JP2008514366A patent/JP5122445B2/ja active Active
- 2006-12-25 KR KR1020087029711A patent/KR20090009951A/ko not_active Ceased
- 2006-12-25 NZ NZ572809A patent/NZ572809A/en not_active IP Right Cessation
- 2006-12-25 WO PCT/JP2006/325813 patent/WO2007129427A1/ja not_active Ceased
- 2006-12-25 MY MYPI20084469A patent/MY149152A/en unknown
- 2006-12-25 BR BRPI0621655-2A patent/BRPI0621655A2/pt not_active IP Right Cessation
- 2006-12-25 CN CN200680054495XA patent/CN101460156B/zh active Active
- 2006-12-25 IN IN2543MUN2008 patent/IN266817B/en unknown
- 2006-12-25 EP EP06835183.2A patent/EP2016939B1/en active Active
- 2006-12-25 CA CA2651596A patent/CA2651596C/en active Active
- 2006-12-25 AU AU2006343077A patent/AU2006343077B2/en active Active
- 2006-12-25 RU RU2008148131/15A patent/RU2428179C2/ru not_active IP Right Cessation
-
2007
- 2007-05-07 US US11/797,722 patent/US7858114B2/en not_active Expired - Fee Related
-
2008
- 2008-10-31 NO NO20084614A patent/NO20084614L/no not_active Application Discontinuation
- 2008-11-09 IL IL195174A patent/IL195174A0/en unknown
-
2010
- 2010-11-17 US US12/948,252 patent/US20110059141A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2016939A1 (en) | 2009-01-21 |
| CN101460156A (zh) | 2009-06-17 |
| BRPI0621655A2 (pt) | 2011-12-20 |
| ES2466647T3 (es) | 2014-06-10 |
| AU2006343077A1 (en) | 2007-11-15 |
| US7858114B2 (en) | 2010-12-28 |
| CA2651596C (en) | 2014-03-25 |
| IN266817B (enExample) | 2015-06-03 |
| AU2006343077B2 (en) | 2012-11-08 |
| RU2428179C2 (ru) | 2011-09-10 |
| JP5122445B2 (ja) | 2013-01-16 |
| KR20090009951A (ko) | 2009-01-23 |
| HK1130175A1 (en) | 2009-12-24 |
| NO20084614L (no) | 2009-02-06 |
| IL195174A0 (en) | 2009-08-03 |
| US20070259028A1 (en) | 2007-11-08 |
| CN101460156B (zh) | 2011-06-08 |
| NZ572809A (en) | 2011-02-25 |
| EP2016939B1 (en) | 2014-03-19 |
| US20110059141A1 (en) | 2011-03-10 |
| RU2008148131A (ru) | 2010-06-20 |
| EP2016939A4 (en) | 2013-01-09 |
| CA2651596A1 (en) | 2007-11-15 |
| JPWO2007129427A1 (ja) | 2009-09-17 |
| WO2007129427A1 (ja) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY149152A (en) | Percutaneous absorption preparations of antimentia drugs | |
| WO2012087047A3 (en) | Percutaneous absorption preparation containing rivastigmine | |
| US20050187212A1 (en) | Pharmaceutical composition for topical delivery of meloxicam | |
| WO2010008893A3 (en) | Anchor systems and methods | |
| WO2007087431A3 (en) | Sublingual fentanyl spray | |
| WO2009017837A3 (en) | Sublingual fentanyl spray | |
| WO2009115562A3 (en) | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts | |
| WO2009066457A1 (ja) | 脂肪酸系イオン液体を有効成分とする外用剤組成物 | |
| WO2009060952A1 (ja) | 新規製剤 | |
| WO2010061386A3 (en) | Pharmaceutical composition and system for permeabilizing fetal membranes | |
| IL160515A0 (en) | Transdermal therapeutic system (tts) with fentanyl as active ingredient | |
| WO2008062446A3 (en) | An extended release composition of levetiracetam, which exhibits no adverse food effect | |
| WO2008000731A3 (en) | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids | |
| WO2010005980A8 (en) | Tacrolimus for improved treatment of transplant patients | |
| WO2008136392A1 (ja) | 経口投与用製剤 | |
| CA2493604A1 (en) | Patch containing fentanyl for mucous membrane of oral cavity | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| WO2007110834A3 (en) | Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | |
| EP1902715A3 (en) | Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function | |
| MY163762A (en) | Therapeutic agent for chronic renal failure | |
| WO2001039752A3 (de) | Transdermales therapeutisches system enthaltend leicht flüchtige wirkstoffe | |
| MY151470A (en) | Controlled release solid preparation | |
| WO2007124700A3 (en) | Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof | |
| NO330805B1 (no) | Anvendelse av et anagrelidmiddel samt transdermal farmasoytisk sammensetning omfattende et slikt middel | |
| WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same |